CRF Announces TCT 2022 Late-Breaking Clinical Science

Newswise – NEW YORK – August 4, 2022 – The Cardiovascular Research Foundation (CRF) has announced the latest clinical science to be presented at TCT 2022. TCT is CRF’s annual scientific symposium and the world’s leading educational gathering specializing in interventional cardiovascular medicine. It will take place September 16-19 in Boston, Massachusetts, at the Boston Convention and Exhibition Center.

Each year, TCT presents cutting-edge research in interventional cardiovascular medicine that directly impacts patient care and how physicians manage heart disease. The 32 selected studies examine the safety and effectiveness of minimally invasive techniques, drugs, technologies and devices that have potential to treat or prevent cardiovascular disease. Cutting-edge science will be presented in the Clinical Science and Endovascular Theater and highlighted during press conferences scheduled for Saturday 17th September, Sunday 18th September and Monday 19th September.

The full program guide can be found here: https://tct2022.crfconnect.com/program-guide. Media representatives are invited to attend TCT and can apply for media credentials at https://tct2022.crfconnect.com/press-registration.

Saturday, 09/17/2022

• Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement: The PROTECTED TAVR Study
• CLASP II D Study: A Randomized Comparison of Transcatheter Edge-to-Edge Repair Devices for Degenerative Mitral Regurgitation – Clinical Outcomes and Echo Findings
• Transcatheter edge-to-edge repair in patients with severe mitral regurgitation and cardiogenic shock: insights from the DVT registry
• Transcatheter aortic valve replacement in small aortic annuli: results from the FRANCE-TAVI registry
• Pathology of Transcatheter Self-Expanding Aortic Valve Failure and Hypoattenuated Leaflet Thickening (HALT)
• 3-Year Results of the Amplatzer™ Amulet™ Left Atrial Appendage Occluder (Amulet IDE) Randomized Controlled Trial
• Three-year results from the randomized SCOPE-I study comparing the ACURATE Neo with the SAPIEN 3 transcatheter heart valve system in patients with symptomatic severe aortic stenosis
• Contemporary clinical and echocardiographic results from over 1000 patients treated with MitraClip™ G4: results of the EXPAND G4 post-approval study
• The PASCAL IID registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive-risk patients with degenerative mitral regurgitation and complex mitral valve anatomy
• Percutaneous or surgical management of ventricular septal defects after infarction: The UK National Register

Sunday 18 September 2022

• Ultrasound endovascular renal denervation for the treatment of uncontrolled hypertension: primary results from the randomized, sham-controlled RADIANCE II pivotal study
• Long-term outcomes after catheter-based renal denervation in patients with uncontrolled hypertension: 3-year follow-up of the SYMPLICITY HTN-3 study
• Pulmonary artery denervation in pulmonary arterial hypertension: A sham-controlled randomized trial
• Results for the FLASH FlowTriever Registry US full cohort for mechanical thrombectomy for pulmonary embolism
• Ultrasound Guidance for Vascular Access in Cardiac Surgery: A Randomized Trial (UNIVERSAL)
• CONFIDENCE Register: Valve hemodynamics and 1-year survival after portico implantation^TM Valve in experienced TAVI centers
• Mediators of improvement in TAVR outcomes over time: insights from the STS-ACC-TVT registry
• Frequency and safety of bioprosthetic valve fractures in patients undergoing valve-in-valve TAVR for failed surgical valves using the SAPIEN 3/Ultra valves: insights from real-world data
• Increased risk of surgical aortic valve replacement after prior transcatheter compared to surgical aortic valve replacement
• Heart damage and quality of life after aortic valve replacement: results of the PARTNER studies
• Mid-term echocardiographic outcomes after transapical mitral valve replacement: updates from the Intrepid pilot study

Monday, 09/19/2022

• Everolimus-eluting stents or bypass surgery for multivessel coronary artery disease: 10-year results of the multicenter, randomized, controlled BEST study
• Survival after PCI or CABG in left main body coronary artery disease: A report from the Swedish Registry of Coronary Angiography and Angioplasty
• A randomized controlled trial to evaluate the value of computed tomography-cardioangiography (CTCA) in improving patient satisfaction and reducing contrast burden, procedure time, and complications in patients who have had prior bypass surgery (CABG) and are undergoing an invasive one undergo coronary angiography
• FAME 3 sub-studies: Clinical outcomes in relation to anatomical vs. functional significance and prognostic value of post-PCI FFR
• Angiographic quantitative flow ratio-guided coronary intervention: two-year results of the FAVOR III study in China
• Randomized, double-blind study of routine early treatment with PCSK-9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
• Prevention of radial artery occlusion with rivaroxaban after transradial coronary procedures: The multicenter, randomized RIVARAD study
• Expansion of stents after intravascular lithotripsy compared to conventional pre-dilatation in calcified coronary arteries
• Cutting balloons to optimize pre-dilation for stenting: The randomized COPS study
• Impact of underlying causes of acute coronary syndrome and 1-year outcomes after percutaneous coronary intervention: results from the optical coherence tomography-guided primary percutaneous coronary intervention registry (TACTICS registry)
• Two-year results of the second-generation randomized drug-eluting stents in diabetes (SUGAR) trial

Get updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.

About CNI and TCT

The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations dedicated to innovation, research and education in interventional cardiology. CRF is dedicated to helping physicians improve the survival and quality of life of people with cardiovascular disease. For over 30 years, CKD has helped accelerate medical breakthroughs and educate physicians on the latest treatments for heart disease. CRF Centers of Excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual CKD scientific symposium and premier educational meeting specializing in interventional cardiovascular medicine. Now in the 34th^th Annually, the TCT features major breakthroughs in medical research, bringing together leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, see www.crf.org and www.tctconference.com.

###